Storia in 3 fonti

Evommune Halts Atopic Dermatitis Program Following Trial Failure - Evommune (NYSE:EVMN)

Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 g fa

Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.

Evommune's EVO756 flops in Phase 2b eczema trial, its second mid-stage miss this summer; MRGPRX2 drug's migraine study continues.